HomeTagsMolecular residual disease

molecular residual disease

Healthcare

Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy

Business Wire - April 19, 2023

Guardant Health, Inc, a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX),...

Biotechnology

Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial

Business Wire - April 13, 2023

Naveris, Inc., a leader in molecular diagnostics for viral cancers, announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by Mayo Clinic. The...